Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Elan Drug Patent Portfolio

Elan's Family Patents


Family Patents



Recent FDA approvals and tentative approvals for Elan

This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.


Generic drugs

Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.

Drug Name Submission class (FDA) Submission Category Submission Date
Potassium Chloride ORIG-1
ⓘ
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
- 28 Jun, 2001


Clinical Trials

Recent Clinical Trials by Elan:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Total Intravenous Anesthesia and Recurrence Free Survival The Cleveland Clinic NA RECRUITING
(Sep 1, 2026)
PHASE3
Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis The Cleveland Clinic NA RECRUITING
(Sep 1, 2026)
PHASE3
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) Leland Metheny NA RECRUITING
(Sep 1, 2026)
PHASE2
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Leland Metheny NA SUSPENDED
(Sep 1, 2026)
PHASE2
Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients: The Cleveland Clinic NA COMPLETED
(Aug 1, 2026)
PHASE3
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma Melanoma Institute Australia NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD The Cleveland Clinic NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2
Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) Haukeland University Hospital NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma Fondazione Melanoma Onlus NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2
Non-Narcotic Pain Control After ACL Reconstruction The Cleveland Clinic NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants Janssen Sciences Ireland UC NA COMPLETED
(May 1, 2026)
PHASE3
Neo-adjuvant Abiraterone Prostate Study Cancer Trials Ireland NA COMPLETED
(Apr 1, 2026)
PHASE2
Radium-223 in Combination With Enzalutamide Cancer Trials Ireland NA COMPLETED
(Apr 1, 2026)
PHASE2
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. Cancer Trials Ireland NA TERMINATED
(Apr 1, 2026)
PHASE2
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. Cancer Trials Ireland NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1
Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure Melana Yuzefpolskaya, MD NA RECRUITING
(Apr 1, 2026)
PHASE1


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List